3
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
- HC Wainwright & Co. analyst Andrew Fein initiated coverage on ImmunityBio, Inc. (NASDAQ:IBRX) with a Buy rating and announced a price target of $8. ImmunityBio …
